Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
BSLN.SW Stock Summary
Top 10 Correlated ETFs
BSLN.SW
In the News
BSLN.SW Financial details
Company Rating
Sell
Market Cap
485.53M
Income
22.6M
Revenue
305.4M
Book val./share
-0.83
Cash/share
5.36
Dividend
-
Dividend %
-
Employees
147
Optionable
No
Shortable
Yes
Earnings
13 Feb 2024
P/E
34.96
Forward P/E
-
PEG
4.1
P/S
2.9
P/B
-9.43
P/C
7.78
P/FCF
114.28
Quick Ratio
1.98
Current Ratio
2.34
Debt / Equity
-11.29
LT Debt / Equity
-9.54
-
-
EPS (TTM)
1.89
EPS next Y
-
EPS next Q
-
EPS this Y
-14.71%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
3.24%
Revenue Q/Q
-14.34%
EPS Q/Q
-166.92%
-
-
-
-
SMA20
10.81%
SMA50
20.59%
SMA100
13.89%
Inst Own
-
Inst Trans
-
ROA
6%
ROE
-23%
ROC
0.13%
Gross Margin
83%
Oper. Margin
13%
Profit Margin
8%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
32.0-49.0
52W High
-14.9%
52W Low
+30.31%
RSI
65
Rel Volume
0.79
Avg Volume
36.33K
Volume
28.58K
Perf Week
1.09%
Perf Month
16.97%
Perf Quarter
11.5%
Perf Half Y
7.89%
-
-
-
-
Beta
0.577
-
-
Volatility
0.39%, 2.39%
Prev Close
1.46%
Price
41.7
Change
2.71%
BSLN.SW Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 12.49 | 12.41 | 12.68 | 12.46 | 13.15 | |
Net income per share | -2.08 | -1.43 | -0.58 | 1.02 | 0.87 | |
Operating cash flow per share | -5.94 | -5.27 | -2.74 | 0.59 | 1.19 | |
Free cash flow per share | -5.97 | -5.49 | -2.81 | 0.32 | 1.1 | |
Cash per share | 12.18 | 16.27 | 12.84 | 7.3 | 5.36 | |
Book value per share | -8.64 | -9.93 | -5.02 | -1.75 | -0.83 | |
Tangible book value per share | -8.68 | -9.99 | -5.07 | -1.8 | -0.88 | |
Share holders equity per share | -8.64 | -9.93 | -5.02 | -1.75 | -0.83 | |
Interest debt per share | 19.16 | 24.47 | 19.69 | 15.33 | 10.72 | |
Market cap | 504.01M | 546.46M | 478.03M | 543.23M | 423.3M | |
Enterprise value | 647.23M | 733.17M | 642.03M | 693.8M | 539.41M | |
P/E ratio | -22.48 | -37.12 | -69.98 | 44.72 | 40.5 | |
Price to sales ratio | 3.75 | 4.28 | 3.23 | 3.68 | 2.69 | |
POCF ratio | -7.9 | -10.09 | -14.93 | 76.99 | 29.72 | |
PFCF ratio | -7.85 | -9.69 | -14.54 | 144.75 | 32.04 | |
P/B Ratio | -5.42 | -5.36 | -8.16 | -26.22 | -42.32 | |
PTB ratio | -5.42 | -5.36 | -8.16 | -26.22 | -42.32 | |
EV to sales | 4.82 | 5.74 | 4.33 | 4.7 | 3.42 | |
Enterprise value over EBITDA | -41.59 | -34.97 | 177.06 | 35.69 | 23.78 | |
EV to operating cash flow | -10.14 | -13.54 | -20.05 | 98.33 | 37.87 | |
EV to free cash flow | -10.08 | -13 | -19.53 | 184.87 | 40.83 | |
Earnings yield | -0.04 | -0.03 | -0.01 | 0.02 | 0.02 | |
Free cash flow yield | -0.13 | -0.1 | -0.07 | 0.01 | 0.03 | |
Debt to equity | -2.13 | -2.37 | -3.74 | -8.25 | -11.29 | |
Debt to assets | 0.89 | 1.05 | 0.89 | 0.77 | 0.65 | |
Net debt to EBITDA | -9.2 | -8.9 | 45.23 | 7.75 | 5.12 | |
Current ratio | 2.45 | 4.46 | 1.38 | 2.34 | 3.2 | |
Interest coverage | -2.07 | -2.29 | 0.11 | 1.48 | 1.23 | |
Income quality | 2.85 | 3.68 | 4.69 | 0.58 | 1.36 | |
Dividend Yield | 0 | 0 | 0.05 | 0 | 0.14 | |
Payout ratio | 0 | 0 | -3.4 | 0 | 5.48 | |
Sales general and administrative to revenue | 0 | 0.23 | 0.2 | 0.21 | 0.21 | |
Research and developement to revenue | 0.76 | 0.76 | 0.63 | 0.5 | 0.49 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.01 | 0.04 | 0.03 | -0.47 | -0.07 | |
Capex to revenue | 0 | -0.02 | -0.01 | -0.02 | -0.01 | |
Capex to depreciation | -0.25 | -0.99 | -0.35 | -1.07 | -0.3 | |
Stock based compensation to revenue | 0.02 | 0.03 | 0.03 | 0.02 | 0.03 | |
Graham number | 20.13 | 17.88 | 8.12 | 6.34 | 4.04 | |
ROIC | -0.16 | -0.17 | 0.01 | 0.1 | 0.16 | |
Return on tangible assets | -0.1 | -0.06 | -0.03 | 0.06 | 0.06 | |
Graham Net | -14.21 | -12.61 | -8.23 | -8.14 | -5.18 | |
Working capital | 109.37M | 173.37M | 66.66M | 100.51M | 104.55M | |
Tangible asset value | -93.33M | -102.72M | -59.24M | -21.29M | -10.55M | |
Net current asset value | -129.57M | -108.31M | -64.81M | -66.2M | -31.15M | |
Invested capital | -2.13 | -2.37 | -3.74 | -8.25 | -11.29 | |
Average receivables | 16.03M | 30.34M | 48.42M | 63.08M | 59.93M | |
Average payables | 6.58M | 9.96M | 11.88M | 5.4M | 3.02M | |
Average inventory | 16.49M | 19.88M | 21.99M | 23.51M | 25.33M | |
Days sales outstanding | 76.85 | 92.64 | 158.81 | 152.42 | 134.64 | |
Days payables outstanding | 130.87 | 199.56 | 160.98 | 2.6 | 79.65 | |
Days of inventory on hand | 359.22 | 321.57 | 345.46 | 330.15 | 359.77 | |
Receivables turnover | 4.75 | 3.94 | 2.3 | 2.39 | 2.71 | |
Payables turnover | 2.79 | 1.83 | 2.27 | 140.33 | 4.58 | |
Inventory turnover | 1.02 | 1.14 | 1.06 | 1.11 | 1.01 | |
ROE | 0.24 | 0.14 | 0.12 | -0.59 | -1.04 | |
Capex per share | -0.04 | -0.22 | -0.07 | -0.28 | -0.09 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2021-12-31 | 2022-06-30 | 2022-12-31 | 2023-06-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 7.96 | 4.95 | 7.46 | 7.09 | 6.06 | |
Net income per share | 1.11 | -1.03 | 2.04 | 2.66 | -1.78 | |
Operating cash flow per share | -0.41 | 0.01 | 0.58 | 1.83 | -0.63 | |
Free cash flow per share | -0.46 | -0.18 | 0.5 | 1.79 | -0.69 | |
Cash per share | 12.71 | 11.98 | 7.24 | 7.59 | 5.36 | |
Book value per share | -4.97 | -5.67 | -1.73 | 1.25 | -0.83 | |
Tangible book value per share | -5.02 | -5.78 | -1.78 | 1.21 | -0.88 | |
Share holders equity per share | -4.97 | -5.67 | -1.73 | 1.25 | -0.83 | |
Interest debt per share | 18.94 | 18.52 | 14.78 | 13.27 | 10.23 | |
Market cap | 482.8M | 456.99M | 547.37M | 506.08M | 423.66M | |
Enterprise value | 646.8M | 641.44M | 697.94M | 584.9M | 539.78M | |
P/E ratio | 9.24 | -9.36 | 5.62 | 3.97 | -4.95 | |
Price to sales ratio | 5.14 | 7.79 | 6.14 | 5.96 | 5.83 | |
POCF ratio | -99.16 | 3.07K | 79.25 | 23.15 | -55.61 | |
PFCF ratio | -89.04 | -209.63 | 92.26 | 23.57 | -51.27 | |
P/B Ratio | -8.24 | -6.8 | -26.42 | 33.76 | -42.35 | |
PTB ratio | -8.24 | -6.8 | -26.42 | 33.76 | -42.35 | |
EV to sales | 6.89 | 10.94 | 7.83 | 6.89 | 7.42 | |
Enterprise value over EBITDA | 38.31 | -73.86 | 24.64 | 15.13 | -33.8 | |
EV to operating cash flow | -132.84 | 4.3K | 101.05 | 26.75 | -70.85 | |
EV to free cash flow | -119.29 | -294.24 | 117.64 | 27.24 | -65.32 | |
Earnings yield | 0.03 | -0.03 | 0.04 | 0.06 | -0.05 | |
Free cash flow yield | -0.01 | 0 | 0.01 | 0.04 | -0.02 | |
Debt to equity | -3.74 | -3.19 | -8.25 | 10.22 | -11.29 | |
Debt to assets | 0.89 | 0.91 | 0.77 | 0.67 | 0.65 | |
Net debt to EBITDA | 9.71 | -21.24 | 5.32 | 2.04 | -7.27 | |
Current ratio | 1.38 | 1.36 | 2.34 | 2.77 | 3.2 | |
Interest coverage | 3.62 | -1.76 | 4.71 | 6.37 | -1.81 | |
Income quality | -0.37 | -0.01 | 0.28 | 0.69 | 0.36 | |
Dividend Yield | 0 | 0 | 0 | 0.03 | 0.05 | |
Payout ratio | 0 | 0 | 0 | 0.54 | -0.89 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0.55 | 0.63 | 0.41 | 0.25 | 0.78 | |
Intangibles to total assets | 0 | 0.01 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.11 | -15.63 | -0.14 | -0.02 | 0.08 | |
Capex to revenue | -0.01 | -0.04 | -0.01 | 0 | -0.01 | |
Capex to depreciation | -1.56 | -6.52 | -1.32 | -0.22 | -0.37 | |
Stock based compensation to revenue | 0.03 | 0.03 | 0.02 | 0.03 | 0.03 | |
Graham number | 11.12 | 11.47 | 8.92 | 8.65 | 5.78 | |
ROIC | 0.1 | -0.06 | 0.17 | 0.2 | -0.15 | |
Return on tangible assets | 0.05 | -0.05 | 0.11 | 0.14 | -0.12 | |
Graham Net | -8.15 | -10.14 | -8.08 | -5.26 | -5.18 | |
Working capital | 66.66M | 56.35M | 100.51M | 118.64M | 104.55M | |
Tangible asset value | -59.24M | -68.41M | -21.29M | 14.46M | -10.55M | |
Net current asset value | -64.81M | -91.45M | -66.2M | -29.22M | -31.15M | |
Invested capital | -3.74 | -3.19 | -8.25 | 10.22 | -11.29 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 0 | 0 | 0 | 0 | 0 | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 61.75 | 59.24 | 62.31 | 68.25 | 71.96 | |
Days payables outstanding | 90.6 | 28.39 | 1.78 | 35.49 | 31.33 | |
Days of inventory on hand | 194.41 | 149.33 | 225.32 | 230.83 | 141.5 | |
Receivables turnover | 1.46 | 1.52 | 1.44 | 1.32 | 1.25 | |
Payables turnover | 0.99 | 3.17 | 50.7 | 2.54 | 2.87 | |
Inventory turnover | 0.46 | 0.6 | 0.4 | 0.39 | 0.64 | |
ROE | -0.22 | 0.18 | -1.18 | 2.12 | 2.14 | |
Capex per share | -0.05 | -0.2 | -0.08 | -0.03 | -0.05 |
BSLN.SW Frequently Asked Questions
What is Basilea Pharmaceutica AG stock symbol ?
Basilea Pharmaceutica AG is a CH stock and trading under the symbol BSLN.SW
What is Basilea Pharmaceutica AG stock quote today ?
Basilea Pharmaceutica AG stock price is $41.7 today.
Is Basilea Pharmaceutica AG stock public?
Yes, Basilea Pharmaceutica AG is a publicly traded company.